收藏切换
The treatment progress on immune checkpoint inhibitors in children with malignant hematological diseases and tumors
收藏切换
Xiaohong QIAO
World Clinical Drug | 2022, 43(8) : 975 - 981
Less
收藏切换
World Clinical Drug | 2022, 43(8): 975-981
• Topic •
The treatment progress on immune checkpoint inhibitors in children with malignant hematological diseases and tumors
Full
Xiaohong QIAO
Affiliations
  • Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China
Published: 2022-08-10 doi: 10.13683/j.wph.2022.08.003
Outline
收藏切换

Programmed cell death protein-1 (PD-1)/programmed cell death 1 ligand-1 (PD-L1) inhibitors have certain antitumor activity on children with recurrent or refractory Hodgkin lymphoma (HL), recurrent or refractory primary mediastinal large B-cell lymphoma, unresectable or metastatic microsatellite instability-high or deficient mismatch repair solid tumor with progression after treatment, recurrent or metastatic Merkel cell carcinoma, especially in children with recurrent or refractory HL. Insufficient expression of PD-1 and PD-L1 can be used as biomarkers to select children who may respond to PD-1/PD-L1 inhibitors. Cytotoxic T lymphocyte antigen-4 inhibitors can be used for the treatment of patients aged 12 and over with unresectable tumors and metastatic melanoma. Immune checkpoint inhibitors (ICIs) are relatively safe and well tolerated. The combined application of multiple ICIs, combined with chemotherapeutic drugs, DNA methyltransferase inhibitors, CD30 antibodies and chimeric antigen receptor T-cell immunotherapy may further improve the curative effect. This article reviewed the research progress of ICIs in the treatment of pediatric hematologic malignancies and tumors in recent years, in order to provide some reference for clinical diagnosis and treatment.

immune checkpoint inhibitor  /  children  /  hematopathy  /  tumor
乔晓红. 免疫检查点抑制剂在儿童恶性血液病及肿瘤治疗中的研究进展. 世界临床药物, 2022 , 43 (8) : 975 -981 . DOI: 10.13683/j.wph.2022.08.003
Xiaohong QIAO. The treatment progress on immune checkpoint inhibitors in children with malignant hematological diseases and tumors[J]. World Clinical Drug, 2022 , 43 (8) : 975 -981 . DOI: 10.13683/j.wph.2022.08.003
Year 2022 volume 43 Issue 8
5
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.08.003
  • Receive Date:2022-01-12
  • Online Date:2026-11-19
  • Published:2022-08-10
Article Data
Affiliations
History
  • Received:2022-01-12
Affiliations
    Department of Pediatrics, Tongji Hospital of Tongji University, Shanghai 200065, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.08.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT